Loading
Every dated change on the records linked to Marginal zone lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Three-year progression-free survival 80.
Five-year event-free survival 68 per cent with chlorambucil and rituximab against 51 and 50 per cent for either alone, with five-year overall survival about 90 per cent in all three arms.